Shilpa Medicare Advances Liver Disease Treatment with New Drug
Shilpa Medicare's Breakthrough Approval for New Drug
Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a prominent manufacturer of active pharmaceutical ingredients (APIs) and formulations, has made significant progress in drug development. The company has recently received approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg. This approval paves the way for marketing authorization focusing on non-alcoholic fatty liver disease (NAFLD).
Understanding Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD represents the most widespread liver disease, impacting roughly 25% of individuals globally, which amounts to around 1.2 billion people. In specific regions, this issue touches about 188 million individuals. If not addressed, NAFLD can deteriorate into a more serious condition known as non-alcoholic steatohepatitis (NASH), which poses life-threatening risks.
Phase-3 Trials Show Positive Outcomes
Shilpa Medicare successfully completed phase-3 clinical trials of Nor UDCA and shared the findings with the SEC. The trial was titled "A phase-III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study," aimed at assessing the safety and effectiveness of Nor UDCA 500 mg in individuals diagnosed with NAFLD.
The trial achieved all primary efficacy endpoints, demonstrating noteworthy advancements in improving the fatty liver stage. Key highlights from the findings include:
Significant Findings
- Liver Fibrosis Reversal: An impressive 83.3% of trial participants exhibited fibrosis reversal, while the remaining participants showed stabilization.
- ALT Normalization: Elevated alanine transaminase (ALT) levels, an essential marker for NAFLD, normalized in nearly 90% of participants within 12 weeks of treatment.
An Innovative Treatment Option
These promising results suggest that Nor UDCA could be a pioneering solution for NAFLD, presenting advantages over traditional UDCA by enhancing its choleretic effect, offering resistance to amidation, showcasing anti-inflammatory properties, and effectively reducing fibrosis.
Company Insights
Mr. Vishnukant Bhutada, the Managing Director of Shilpa Medicare, expressed optimism about the SEC's approval, stating, "We are thrilled with this approval from the SEC and look forward to obtaining marketing authorization soon. Our commitment lies in collaborating with regulatory bodies to expedite bringing this innovative treatment to patients. We are hopeful to launch it soon. This new chemical entity approval illustrates Shilpa's dedication to innovating affordable healthcare, particularly addressing the urgent needs of a vast patient population. Following the approval in our region, we aim to connect with global regulatory authorities to seek scientific guidance for international introduction of this novel product."
A Legacy of Quality Healthcare Solutions
Established in 1987, Shilpa Medicare has consistently focused on manufacturing APIs, formulations, and biologics, meeting the quality standards of major regulatory agencies. Additionally, the company is acknowledged for delivering comprehensive turnkey Contract Development and Manufacturing Organization (CDMO) solutions to a global clientele.
Frequently Asked Questions
What is Nor Ursodeoxycholic Acid?
Nor Ursodeoxycholic Acid is a novel tablet approved for treating patients with non-alcoholic fatty liver disease.
What are the benefits of Nor UDCA?
The benefits of Nor UDCA include effective liver fibrosis reversal and normalization of ALT levels in patients within a short treatment duration.
What is the significance of the SEC's approval?
The SEC's approval is a critical milestone allowing Shilpa Medicare to move forward with marketing Nor UDCA for mainstream treatment of NAFLD.
How will this drug impact patients?
This treatment has the potential to significantly improve the quality of life for NAFLD patients by addressing both the disease and its symptoms effectively.
What other healthcare solutions does Shilpa Medicare provide?
Shilpa Medicare offers a wide range of APIs, formulations, and biologics services, including comprehensive CDMO solutions for clients globally.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
